explore -WSS

explore

author：focus 2025-09-27 23:33:02 - browse：188

A pharmacist hands a box of Wegovy — first opinion coverage from STAT — Bloomberg photo by George Frey

LONDON — Novo Nordisk said Wednesday that it had started to increase the availability of its blockbuster obesity drug Wegovy for new patients in the United States, after massive demand and a supply crunch had led it to limit doses last May.

The announcement that Novo was making more of its lower-dose starter product available as of this month came as the company reported its 2023 earnings, with sales up by 36% and operating profit up 44% at constant exchange rates, driven by enormous sales of Wegovy and Ozempic, the company’s sister drug for diabetes. The company also projected double-digit growth in sales and operating profit for 2024.

“I am pleased to state that we are now enabling more new U.S. patients to initiate treatment by more than doubling the amount of lower-dose strength Wegovy compared to previous months,” Novo CEO Lars Fruergaard Jørgensen said on a call with reporters.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Maker of FluMist seeks to allow at

entertainment

WSS

Biden's order seeks to regulate AI risk without stifling innovation

FDA approves Eli Lilly ulcerative colitis treatment Omvoh

Cancer thrives by mutating. But sometimes, a mutation leaves it vulnerable

Readout Newsletter: The latest from Bristol, Sarepta, and Novartis

Senate panel to vote on hospitals, PBMs, prisoner care

Emergency medicine has repudiated 'excited delirium.' Now what?

hotspot

explore

hotspot

Medicare proposal to cover medical devices draws a mixed reaction

Medtronic CEO on promising devices for diabetes, hypertension

Heart attack and stroke risk calculators need revising

Cassava reveals details — and problems — with Alzheimer's study

How to save PrEP access — and even expand it

Curing rare childhood diseases will falter unless Congress steps up

Tori Bowie and the unacceptable rates of Black maternal death

Cassava reveals details — and problems — with Alzheimer's study

Malaria cases in Florida and Texas: Here’s what you need to know

Cancer thrives by mutating. But sometimes, a mutation leaves it vulnerable

explore

The system is set up to fail children with medical complexity

Readout Newsletter: What happened with Sarepta's Duchenne data

Maker of FluMist seeks to allow at

Pharma companies must ensure equitable access to obesity drugs

Traditional Chinese medicine benefits explored in new JAMA study

Medtronic CEO on promising devices for diabetes, hypertension

focus

leisure time

entertainment

Wikipedia